ReAlta’s PIC1 Platform
A New Drug Class
The ReAlta technology platform, termed “PIC1”, is a family of over 75 engineered peptides. This platform is uniquely multi-modal, with:
- Complement Inhibition +
- MPO Inhibition +
- NETosis Inhibition +
- Antioxidant Activity +
- Antimicrobial Activity +
Lab and animal research show this platform has the potential to provide game-changing therapy for over 25 unmet or under-addressed medical needs.
PIC1 Complement Inhibition
Schematic overview of the complement system.
PIC1 binds to the C1q and MBL, the initiator molecules of the classical and lectin complement pathways, respectively, blocking downstream effector functions. PIC1 does not inhibit alternative complement pathway activation which is critical for immune surveillance against invading pathogens.
Excellent Safety Profile
PIC1 appears to have an excellent safety profile. In toxicity testing thus far, over 500 rat pups have been treated with large doses of PIC1 without side effects. PIC1 also possesses intrinsic anti-microbial properties.
Scientific Review and Support
The PIC1 platform has had widespread scientific review and support. Scientists conducting research on PIC1 capabilities have published 18 peer-reviewed and indexed studies. Grant funding supported development of PIC1 has been awarded by a number of sources, including the NIH, National Multiple Sclerosis Foundation, Cystic Fibrosis Foundation and the Commonwealth Transfusion Foundation.